Survival in people with poor-prognosis epithelial ovarian cancer
Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma
We will collect clinical and tumor information to see if people with recurrent epithelial ovarian cancer who have a progression-free survival of 6 months or less have different survival outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Rome) |
| Trial ID | NCT07540403 on ClinicalTrials.gov |
What this trial studies
This observational project will register consecutive adults with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who experienced recurrence with a progression-free survival (PFS) of 6 months or less. Investigators will enter anonymized clinical, pathological, and prognostic data into a central database. The dataset will be analyzed to describe survival patterns and to explore clinical or tumor features associated with poorer outcomes. No experimental treatments are given as part of the protocol; the work is a retrospective/prospective registry to refine prognostic categorization.
Who should consider this trial
Good fit: Adults (age ≥18) with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, a PFS ≤6 months for the recurrent disease, ECOG performance status ≤2, and who provide consent for use of their data.
Not a fit: People with non-epithelial ovarian tumors, a PFS >6 months, or who are under 18 are not eligible and would not be expected to benefit from participation.
Why it matters
Potential benefit: If successful, the analysis could help identify subgroups with especially poor prognosis and inform future treatment decisions and trial eligibility criteria.
How similar studies have performed: Previous observational registries and analyses have linked short PFS to poorer outcomes, so this work builds on existing evidence rather than testing a novel therapy.
Eligibility criteria
Show full inclusion / exclusion criteria
1. INCLUSION CRITERIA * Patients diagnosed with histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma with a PFS ≤6 months. * Age ≥18 years. * Any FIGO (Federation of Gynecology and Obstetrics) stage at diagnosis. * Signed informed consent for the use of personal data for research purposes. * ECOG performance status ≤2. 2. EXCLUSION CRITERIA * Age \<18 years. * Patients with non-epithelial ovarian carcinoma. * Patients with a PFS \>6 months.
Where this trial is running
Rome
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Rome, Italy (Recruiting)
Study contacts
- Principal investigator: Claudia Marchetti — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study coordinator: Claudia Marchetti
- Email: claudia.marchetti@policlinicogemelli.it
- Phone: 00393935860248
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.